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Background: CBT recipients may respond to post-transplant
vaccines differently than other transplant groups due to the
lack of transfer of donor immunity.
Methods: We analyzed vaccine responses in 48 CBT recipi-
ents transplanted at our center from 2005-2010 for the
treatment of hematologic malignancies with myeloablative
or non-myeloablative conditioning. GHVD ppx included
a calcineurin-inhibitor and MMF. All patients received
double unit CB grafts and no pt received ATG. Vaccination
criteria included CD4+ cell count > 200 cells/ul and IgG level
> 500 mg/dl at > 6 weeks following the last IVIG dose.
Results: Forty-eight of 69 (70%) eligible pts alive & disease-
free @ 12 months post-HCT were vaccinated. Vaccinated
patients engrafted with 6/6 (n ¼ 2), 5/6 (n ¼ 26), or 4/6 (n ¼
20) HLA-matched units. Twelve pts received rituximab
(median 4 doses) as planned peri-transplant therapy for B-
cell malignancies (n ¼ 6), EBV viremia/ lymphoma (n ¼ 3),
autoimmune hemolysis (n ¼ 1), pure red cell aplasia (n ¼ 1),
or recurrent disease (n¼1). Prior to immunization, 13
patients had no acute or chronic GVHDwhereas 35 had prior
grade II-IV acute and/or chronic GHVD. Overall, the median
time to vaccination was 16.9 months post-CBT; 18.9 months
in pts who received rituximab; 15.23 months in those who
did not (P¼ .056). Pre-vaccination titers obtained at amedian
of 1 yr demonstrated that> 85% of patients lacked protection
against pneumococcus, H. ﬂu, and pertussis and > 50%
lacked immunity against tetanus, measles, & mumps. Sero-
conversion or > 3- fold rise in titer was observed in > 60% of
patients in response to tetanus, diphtheria, H. ﬂu, polio and
pneumococcal (PCV7 or PCV13) vaccines. Following 3 doses
of rHBV vaccine, 52% pt seroconverted. Only 2/35 recipients
of a single Tdap developed protective pertussis titers; 0/8 pts
responded to a single protein-conjugated meninogoccal
vaccine. To date, 20 pts including 9 adults have received an
MMR at a median of 2.3 years post-CBT. 8 pts received the
live attenuated varicella vaccine. To date, seroconversion
following measles, mumps, & rubella vaccine occurred in
56%, 41% & 93% of pts, respectively and 5 evaluable pts
seroconverted after 1 (n¼3) or 2 doses of Varivax (n ¼ 2).
Survival in vaccinated patients is 100%. No serious reactions
to any vaccine occurred.
Conclusion: CBT recipients, including adults & those with
prior GVHD or rituximab therapy, are capable of responding
to tetanus, diphtheria, H. ﬂu, polio & PCV7 or PCV13 similar
to other transplant groups. The sub-optimal response to
pathogens associated with outbreaks in the community
(Hepatitis B, Pertussis, meningococcus, measles, mumps,
varicella) highlight the need to obtain pre- & post-vaccine
titers to document response, and the need to deﬁne the
optimal vaccination regimen in this population.191
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The rate of immune reconstitution (IR) is directly correlated
with thenumberofhematopoietic stemcells (HSC) infusedand
is particularly delayed in patients undergoing cord blood
transplantation (CBT) secondary to the limited numbers of
HSC. Thus, methods to increase the number of cord blood (CB)
progenitors have the potential to accelerate IR after CBT.
Natural killer (NK) cells play a crucial role in early IR after HCT
because they are the ﬁrst lymphocyte subset to recover after
transplant. CB NK cells have been reported to have incomplete
maturation and require activation for effective function. Here,
we report a clinically relevant method for ex vivo expansion of
NKcells isolated fromCBwithout theuseof a stromal layer.Our
group has demonstrated that CB NK cells cultured in the
presence of IL-2 and IL-15 results in amulti-log increase in the
number of precursors that have a signiﬁcant increase in cyto-
toxicity against several target cancer cell lines. After 21 days in
culture, there is a 1.848 0.341 log fold increase in the number
of CD3-CD56+ NK cells (range, 0.420 to 3.108) (P < .001, N¼9).
After culture, we also found a signiﬁcant 2.612 0.310 log fold
increase (range, 0.979 to 3.622) (P< .001, N¼9) in the number
of CD3+CD56+ NKT cells. Evaluation of cytotoxicity against
K562cells, a chronicmyelogenous leukemia, showedtherewas
also a signiﬁcant increase in cytolytic function at days 14 (31.52
 8.317% target cell lysis, P< .01, N¼8) and 21 (44.22 9.866%
target cell lysis, P< .01, N¼8) in culturewhen compared to day
of isolation; similar results were seen using Jurkat cells, an
acute T-cell lymphoblastic leukemia (T-ALL). Evaluation of NK
cell resistant cells lines was also tested. While we found an
increase in cytotoxicity toward the myeloid lymphoid
leukemia cell line (MLL), MV411, after culture, the RS411 (MLL/
ALL) and HDLM2 (Hodgkin's lymphoma) cell lines remained
resistant to cytolytic killing (N¼3). Currently, we are investi-
gating the NK cell population(s) responsible for the cytotoxic
killing and the corresponding killer cell Ig-like receptor (KIR)
ligand/adhesion molecule(s) that may be responsible for
function. We hypothesize that using methods to increase the
number of CB NK cells have the potential to prevent early
relapse, infections and graft versus host disease, as well as
facilitate engraftment when administered following CBT.
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Tissue engineering approaches based on implantation of
biomimetic three-dimensional (3D) tissue constructs have
been used for more than a decade for in vivo regeneration of
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neering of functional lymphoid tissues is challenging due to
the speciﬁc requirements for lymphoid differentiation and
has barely been accomplished to date. The aim of this study
was to develop a method for engineering of a T cell devel-
opment supporting 3D microenvironment and to assess if
implantation of such a tissue construct is feasible and results
in thymus-independent T cell development in vivo.
We fabricated 3D scaffolds using the FDA-approved
biodegradable polyester polycaprolactone (PCL) as well as
PCL/collagen composites. The scaffold architecture was
designed to provide mechanical and geometrical properties
necessary to support cell growth, proliferation,differentiation,
and motility. We utilized a layer-by-layer assembly approach
to fabricate structures that consisted of alternating thin
nanoﬁber layers and thick microﬁber layers (A, B). Nanoﬁber
layers were fabricated by electrospinning from a PCL/collagen
solution. These layers were functionalized by vascular endo-
thelial growth factor incorporation topromote vascularization
and seeded with OP9-DL1 stromal cells to provide Notch
signaling. Microﬁber layers were highly porous structures
fabricated from PCL by salt leaching, and were encapsulated
with a biomimetic dextran-based hydrogel containing in vitro
generated T lineage committed lymphoid precursor cells as
well as growth factors, cytokines and chemokines required for
T cell development (A, B). The layer-by-layer assembled
structurewith alternating layersof nanoﬁbers andmicroﬁbers
provided optimal support for stromal cell growth while facil-
itating angiogenesis and T lineage cell expansion and migra-
tion enabled by the highly porous microﬁber layers.
Subcutaneous implantation of layer-by-layer tissue
constructs into athymic nude mice resulted in rapid vascu-
larization. Implanted T lineage cells could be detected by in
vivo bioluminescence imaging at the implantation site (C) for
more than 1 month, and progeny of these cells efﬁciently
reconstituted secondary lymphoid organs of both allogeneic
and syngeneic recipients. Flow cytometric analysis of donor
cells in lymph nodes, spleen, and the implant 4 weeks after
implantation identiﬁed both CD4 and CD8 single positive T
cells as well as CD4 and CD8 double positive T cells and NKT
cells. The majority of T cells had an effector memory pheno-
type (but central memory and naïve cells were also present).We conclude that thymus-independent in vivo T cell
generation in a tissue-engineered artiﬁcial microenviron-
ment is feasible, and further development of this technology
is expected to produce an exciting innovative strategy for the
treatment of T cell deﬁciency.
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Injection of lymphoid organs such as the thymus in mice
is a valuable tool at the disposal of developmental biologists
and immunologists. In this study we performed for the ﬁrst
time freehand percutaneous ultrasound-guided intrathymic
injections in a variety of mouse models to develop novel
strategies promoting T cell immunity.
We found that in vitrogenerated T cell precursors can efﬁ-
ciently be delivered via injection into the thymus of a suble-
thally irradiated allogeneic recipient 3 h after irradiation, and
this procedure signiﬁcantly improved T cell reconstitution. As
expected, cell injection into the thymus of non-irradiated
syngeneic recipients resulted in low levels of thymic reconsti-
tution, indicating that in the absence of rejection the number of
availableniches forprecursor cells is still amajor limiting factor.
We next assessed if it was feasible to inject the thymus of mice
with signiﬁcantlydecreased thymicvolumesecondary toeither
age-related thymic involution or radiation-induced injury
(injection 24 h after irradiation). Even though challenging, we
were able to perform accurate injections of the target on both
settings, highlighting the potential of this approach for the
development of protocols to treat aging populations, as well as
for radiation countermeasure development.
We next studied the fate of intrathymically injected bone
marrow-derived progenitor cell populations including less
committed Lin-Sca-1+c-kit+ (LSK) cells and lymphoid-
primed multipotent progenitor cells. We found that espe-
cially LSK cells had excellent thymus-repopulating capacity
and their progeny almost exclusively committed to the T cell
lineage. Intrathymic injection of LSK cells into recipients of
a T-cell depleted BMT resulted in enhanced T cell reconsti-
tution on day +28.
We ﬁnally evaluated the efﬁcacy of 3 known thymopoietic
factors (interleukin 7 (IL-7), interleukin 22, keratinocyte
growth factor) when injected into the thymus before or after
irradiation. Only injection of IL-7, 3 h after irradiation resulted
in increased thymic cellularity on day +14. However, a single
injection of each of the 3 agents 24 h prior to irradiation
resulted in a 2 to 4-fold increase in thymus size by day +28.
In addition to the thymus, lymph nodes provide an even
easier, already clinically validated target. Importantly, lymph
nodes have been found to support extrathymic T cell devel-
opment during periods of lymphopenia. When T lineage
committed precursor cells were injected into single axillary
lymph nodes of irradiated nude mice, stable engraftment
was found and 4 weeks after injection, the majority of
recovered donor-derived cells were CD8+ T cells with
a central memory phenotype.
Our ﬁndings indicate that imaging-guided freehand
injection of lymphoid organs is feasible, safe, accurate, time
